Journal article
Early response to benralizumab in Canadian patients with severe eosinophilic asthma: Interim results from a prospective observational cohort
Abstract
RATIONALE: There is a need to characterize the real-world impact of benralizumab, an anti-interleukin-5 receptor alpha antibody, for add-on maintenance therapy of patients with severe eosinophilic asthma. The objective of this study was to assess change in patient-reported outcomes following initiation of benralizumab, focusing on asthma control, quality of life (QoL), and work and activity impairment. This is an interim analysis of the …
Authors
Noorduyn SG; Kayaniyil S; Lancaster B; Dorscheid D; Tourin O; Walker B; Thawer A; Ramesh W; Khan I; Kim H
Journal
Canadian Journal of Respiratory Critical Care and Sleep Medicine, Vol. 8, No. 3, pp. 99–107
Publisher
Taylor & Francis
Publication Date
May 3, 2024
DOI
10.1080/24745332.2024.2339195
ISSN
2474-5332